Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 10/20 | 0.39 |
| ▸ | RXRA | P19793 | 10/20 | 0.39 |
| ▸ | RXRG | P48443 | 7/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3291286 | 0.98 | RXRB (0.39) | RXRBRXRARXRGCXCR2MAOA | |
| SCHEMBL3290312 | 0.81 | CXCR2 (0.36) | RXRBRXRARXRGCXCR2MAOB | |
| SCHEMBL3292337 | 0.81 | RXRB (0.44) | RXRBRXRARXRGMRGPRX4TSHR | |
| SCHEMBL3291395 | 0.80 | HPD (0.37) | RXRBRXRARXRGMAOBTSHR | |
| SCHEMBL3288879 | 0.79 | CXCR2 (0.35) | RXRBRXRARXRGCXCR2MAOA | |
| SCHEMBL3290684 | 0.78 | CHRNA7 (0.40) | RXRBRXRARXRGMAOAMAOB | |
| SCHEMBL3293273 | 0.77 | HPD (0.38) | RXRBRXRARXRGMAOAMAOB | |
| SCHEMBL23858971 | 0.76 | RXRB (0.41) | RXRBRXRARXRGCXCR2MAOA | |
| SCHEMBL3291871 | 0.76 | RXRB (0.39) | RXRBRXRARXRGCXCR2MAOA | |
| SCHEMBL3294566 | 0.74 | MEN1 (0.43) | CXCR2MAOBRAB9APRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728155-B2 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH LLC (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1675842-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Wyeth (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005040146-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WYETH (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | HTR2C, HTR1A, HTR1B | RXRB 1186/4885RXRA 1269/4885RXRG 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.